Innovative medicines business

Novartis’s (NVS) innovative medicines business represents the prescription products business and includes two units: Novartis Pharmaceuticals and Novartis Oncology. The Innovative Medicines segment includes various products like cardiovascular and metabolics products, respiratory products, neuroscience products, dermatology products, immunology products, oncology products, and established products.

Novartis’s Innovative Medicines Business in 4Q17

The above chart compares the revenues for the innovative medicines segment since 1Q16.

Performance of innovative medicines

Overall, the innovative medicines business accounted for ~67.8% of Novartis’s total revenues. The segment reported revenues of $8,756 million during 4Q17, which includes 4% growth in operating revenues, while there was a 2% positive impact of foreign exchange during 4Q17 as compared to 4Q16.

The increase in revenues was driven by strong sales of cardiovascular and metabolic products, immunology and dermatology products, neuroscience products, oncology products, ophthalmology products,  and respiratory products, partially offset by lower sales of established medicines.

For cardiovascular and metabolic products, the revenue growth was driven by strong sales of Entresto and other products.

For immunology and dermatology products, the growth was driven by strong sales of products including Cosentyx,  Ilaris, Myfortic, and Zortess/Certican, partially offset by lower sales of Neoral and other products.

For neuroscience products, the growth was driven by strong sales of Gilenya, offset by lower sales of other products.

For oncology products, the growth was driven by strong sales of Afinitor/Votubia, Exjade/Jadenu, Jakavi, Kisqali, Promacta/Revolade, Sandostatis, Tasigna, Tafinlar and Mekinist, and Votrient, substantially offset by lower sales of Gleevec/Glivec and other oncology products.

For ophthalmology products, the growth was driven by strong sales of Lucentis, Systane group, and Topical Olopatadine group, partially offset by lower sales of Travoprost group and other products.

For respiratory products, the growth was driven by strong sales of Seebri Breezhaler, Ultibro Breezhaler, and Xolair, partially offset by lower sales of Onbrez Breezhaler and other products.

For established products, the revenues declined due to lower sales of Diovan/Co-Diovan, Voltaren/Cataflam, Exelon/Exelon patch, and other products, partially offset by growth in sales of Exforge, Galvus, and Ritalin/Focalin sales.

The PowerShares International Dividend Achievers ETF (PID) holds 10.5% of its total investments in healthcare companies. PID holds 1.4% in Novartis AG (NVS), 1.4% in Sanofi (SNY), 4.6% in Teva Pharmaceuticals (TEVA), and 1.0% in Novo Nordisk (NVO).

Latest articles

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let's take a closer look at each.

Walt Disney’s (DIS) latest movie, Toy Story 4, has reportedly broken records in the opening weekend with $118 million in sales. However, the opening weekend collection was behind analysts’ expectations of at least $150 million in the first weekend.

24 Jun

Will Home Depot’s Upward Momentum to Continue?

WRITTEN BY Rajiv Nanjapla

As of June 21, Home Depot (HD) was trading at $209.39, which implies a rise of 9.7% since the announcement of its first-quarter earnings on May 21. Also, the company was trading at a premium of 32.4% from its 52-week low of $158.09 and a discount of 2.8% from its 52-week high of $215.43.

On June 21, Aurora Cannabis (ACB) made an announcement that indicated that it will move towards higher margin vape products. In addition, the company also believes concentrates and edibles will command higher margins. In anticipation of this development, the company announced the expansion of its facility to capitalize on growth related to these segments.

Shares of Mondelēz International (MDLZ) are scaling new heights thanks to its stellar gains so far this year. Mondelēz stock is up 38.0% on a YTD (year-to-date) basis, and it closed at $55.25—just a shade lower than its 52-week high of $55.71—on June 21.

24 Jun

How Long Will Facebook's Libra Fuel Bitcoin Rally?

WRITTEN BY Mayur Sontakke, CFA, FRM

Ever since the news about Facebook’s (FB) cryptocurrency project broke, Bitcoin has rallied on the hope that Facebook’s entry in the space will help make cryptocurrencies mainstream. Facebook’s cryptocurrency will be called Libra and will be governed by an association with 28 founding members across industries.

172.31.38.64